High throughput screening is primarily used in the drug discovery application with the help of software tools, sensors, detectors, and liquid handling devices. The genetic, chemical and pharmacological testing is performed on the different chemicals to test and validate the presence of essential active compounds, genetic interactions, and bio-molecular interactions. The investment in development of new and improved drugs has increased significantly during last decade. This has resulted in adoption of advanced technologies in methods and procedure used for drug discovery. As it is a complex process and requires sophisticated hardware and software, thus high throughput screening technique has been widely adopted across the pharmaceutical manufacturing industry. Adoption of open innovation models in pharmaceutical manufacturing, and increasing research activities are anticipated to compliment the growth of high throughput screening (HTS) market in coming years.
North America contributed the largest share to the global high throughput screening (HTS) market in 2019 owing to increased investment in research & development and manufacturing of biopharmaceuticals. Additionally, pharmaceutical manufacturing and biotechnology companies are focusing on development of advanced therapeutic drugs to cater the rising demand. This is anticipated to contribute towards the growth of high throughput screening market in North America. Asia Pacific’s high throughput screening market is anticipated to witness prominent growth during the forecast owing to expanding pharmaceutical and healthcare equipment manufacturing industry in China, India, South Korea, and other Southeast Asian countries.
The report titled “High Throughput Screening (HTS) Market - Global Market Share, Trends, Analysis and Forecasts, 2022-2032” wherein 2020 is a historic period, 2021 is the base year, and 2022 to 2032 is forecast period. Additionally, the study takes into consideration the competitive landscape, wherein the report would provide company overview and market outlook for leading players in the global high throughput screening (HTS) market. Furthermore, the report would reflect the key developments, global & regional sales network, business strategies, research & development activities, employee strength, and key executive, for all the major players operating in the market. For instance, Danaher Corporation reported revenues of USD 17,911.1 million in 2019 and the product segment analysis of the company indicates that the Life Sciences business segment of the company dominated revenue in 2019.
The global high throughput screening (HTS) market is segmented based on component, technology, detection method, application, and end user. Based on component, the global high throughput screening (HTS) market is segmented into equipment, software, and services. The equipment is further sub-segmented into reagents and assay kits, instruments, consumables, and accessories. Based on technology, the global high throughput screening (HTS) market is segmented onto cell base assay, lab-on-a-chip, ultra-high throughput screening, bioinformatics, and lab free technology. The cell-based assay is further sub-segmented into 2D cell culture, 3D cell culture, profusion cell culture, and reporter-based assay. The 3D cell culture is further sub-segmented into scaffolding based technology (hydrogels: animal-derived hydrogels, Matrigel, collagen, synthetic hydrogels, alginate/agarose, inert matrix/solid scaffolds, and micropatterned surfaces), and scaffolding free technology (microplates, hanging-drop plates, ultra-low binding plates, and others). Based on detection method, the global high throughput screening (HTS) market is segmented into mass spectrometry (MS), chromatography, calorimetry, x-ray diffraction, and other. Based on application, the global high throughput screening (HTS) market is segmented into drug discovery, chemical biology programs, cell- & organ-based screening, biochemical screening, biological active compound screening, genomics, proteomics, and others. The drug discovery applications are further sub-segmented into target identification and validation, primary and secondary screening, toxicology assessment. Based on end user, the global high throughput screening (HTS) market is segmented into pharmaceutical and biotechnology companies, academic and government institutes, and others. Based on geography, the global High throughput screening (HTS) market is segmented into North America, Europe, Asia Pacific, Middle East & Africa, and South America.
The research provides in-depth analysis of prominent players holding the majority share of the global market with a focus on all operating business segment, and would identify the segment of the company focusing on high throughput screening (HTS). Further, market share of prominent companies in the global high throughput screening (HTS) market would also be estimated. For instance, Danaher Corporation operates through three business segments namely Life Science, Diagnostics, and Environmental & Applied Solutions. The high throughput screening (HTS) products are delivered under Life Science business segment of the company with revenue contribution of US$ 7.0 billion in 2019.
The study takes into consideration the key competitive information such as business strategy, product portfolio, key development, SWOT analysis, and research and development focus of all the high throughput screening (HTS) device manufacturing companies and technology providers. Furthermore, the global high throughput screening (HTS) market study would take into consideration the participants engaged throughout the ecosystem of the market, along with their contribution. Product portfolio would focus on all the products under the high throughput screening (HTS) business segment of the company. Similarly, the recent development section would focus on the latest developments of company such as strategic alliances and partnerships, merger and acquisition, new product launched and geographic expansion in the global high throughput screening (HTS) market.
Major players operating the global high throughput screening (HTS) market include Agilent Technologies, Inc., Aurora Biomed, Axxam S.p.A., Bio-Rad Laboratories, Danaher Corporation, Hamilton Company, Merck Millipore, PerkinElmer, Inc., Tecan Group Ltd., and Thermofisher Scientific, Inc.
InsightSLICE adopts a research methodology which is highly meticulous and comprehensive, yielding accurate research results. Our research methodology utilizes data triangulation model which helps in the precise collection and validation of information. Our set processes for problem solving and paid primary tools guarantee that any client requirement is met with utmost diligence and accuracy. Some of the primary components that are consequential to our research approach are:
Secondary Research or Desk Research
Distinctive Data Model
Secondary Sources include but are not limited to:
Past Published Research
Historical Data and Information
Primary Sources include but are not limited to:
InsightSLICE also leverages three types of data triangulation approaches as follows:
Data Source Triangulation
Extracting data and validation from multiple type of secondary and primary sources
Combining various methodologies to validate data inputs
Applying different theories to check credibility of data sets
North America contributed the largest share to the global high throughput screening (HTS) market in 2019 owing to increased investment in research & development and manufacturing of biopharmaceuticals.
Adoption of open innovation models in pharmaceutical manufacturing, and increasing research activities are anticipated to compliment the growth of high throughput screening (HTS) market in coming years.